D J Preiss

Summary

Country: UK

Publications

  1. ncbi Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
    D J Preiss
    Department of Biochemistry, Glasgow Royal Infirmary, Glasgow, UK
    Int J Clin Pract 61:697-701. 2007
  2. ncbi Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results
    David Preiss
    Department of Biochemistry, Glasgow Royal Infirmary, Castle Street, Glasgow, UK
    Ann Clin Biochem 45:70-5. 2008
  3. ncbi Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
    David Preiss
    British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, Scotland, UK
    Clin Sci (Lond) 115:141-50. 2008
  4. ncbi Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
    David Preiss
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Clin Endocrinol (Oxf) 70:815-28. 2009

Collaborators

Detail Information

Publications4

  1. ncbi Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
    D J Preiss
    Department of Biochemistry, Glasgow Royal Infirmary, Glasgow, UK
    Int J Clin Pract 61:697-701. 2007
    ..If the results are positive, further investigations should derive to what extent blockade of VCAM-1 by succinobucol, rather than its other effects, accounts for the reduction in vascular events...
  2. ncbi Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results
    David Preiss
    Department of Biochemistry, Glasgow Royal Infirmary, Castle Street, Glasgow, UK
    Ann Clin Biochem 45:70-5. 2008
    ..2 cases/100,000/year by following up abnormal TFTs. The aim of this study was to verify the incidence of unsuspected hypopituitarism diagnosed by reflective testing on such samples in a Scottish population...
  3. ncbi Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
    David Preiss
    British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, Scotland, UK
    Clin Sci (Lond) 115:141-50. 2008
    ..Furthermore, the cost/benefit ratio of any new therapies, and any potential harms, must be evaluated carefully before being clinically advocated...
  4. ncbi Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence
    David Preiss
    BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Clin Endocrinol (Oxf) 70:815-28. 2009
    ..Ongoing studies such as ACCORD, IMPROVE-IT, ASCEND, ORIGIN and HPS2-THRIVE should assist in answering outstanding questions over the next 5 years...